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Abstract 
Curcumin is a natural product with a broad spectrum of beneficial properties relating to pharmaceutical ap-
plications, extending from traditional remedies to modern cosmetics. The biological activity of such pig-
ments, however, is limited by their solubility and bioavailability, thereby necessitating new ways of achiev-
ing optimal tissue cellular response and efficacy as drugs.  Metal ion complexation provides a significant 
route toward improvement of curcumin stability and biological activity, with vanadium being a representa-
tive such metal ion, known for its presence in biological systems and its exogenous biological activity in po-
tential pharmaceuticals.  Driven by the need to optimally increase curcumin bioavailability and bio-activity 
through complexation, synthetic efforts were launched to seek out stable species, ultimately leading to the 
synthesis and isolation of a new ternary V(IV)-curcumin-(2,2’-bipyridine) complex.  Physicochemical char-
acterization (elemental analysis, FT-IR, TGA, UV-Visible, NMR, ESI-MS, Fluorescence, X-rays) portrayed 
the solid-state and solution properties of the ternary complex.  Pulsed EPR spectroscopy, in frozen solutions, 
suggested the presence of two species, cis- and trans-conformers.  DFT calculations revealed the salient fea-
tures and energetics of the two conformers, thereby complementing EPR spectroscopy.  The well-described 
profile of the vanadium species led to its in vitro biological investigation involving toxicity, cell metabolism 
inhibition in cultures of S. cerevisiae, ROS-suppressing capacity, lipid peroxidation, and plasmid DNA deg-
radation.  A multitude of bio-assays and methodologies in comparison to free curcumin, showed that it ex-
hibits its antioxidant potential in a concentration-dependent fashion, thereby formulating a bioreactivity pro-
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file supporting development of new potentially efficient hybrid vanado-pharmaceuticals, targeting (ex-
tra)intra-cellular processes under (patho)physiological conditions.  
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Curcumin (diferuloylmethane) is a well-known natural pigment with good stability and low toxicity, the 
metal coordination chemistry of which has been only partially explored [1-4].  It is obtained from the rhi-
zomes of the traditional herbal remedy and dietary Indian spice turmeric (Curcuma longa Linn.) [5,6].  It is 
used in cosmetics, spices, and traditional medicines, particularly in the Orient.  As an organic physiological 
substrate, curcumin shows good optical and electrical properties, owing to the symmetric structure contain-
ing a β-diketone moiety and an extensive π-conjugation system in polar media [7,8]. 
Systematic investigations of curcumin reveal a wide spectrum of beneficial properties, exemplifying antiox-
idant, anti-inflammatory, antimicrobial, and anticancer activities [9-14].  Curcumin protects neurons against 
amyloid-β (Aβ) peptide toxicity, due to its selective binding to amyloid plaques, as already proven through 
experiments on transgenic mouse models in Alzheimer’s disease (AD) [15,16].  It is also known to exhibit 
photo-activated cytotoxicity by inducing apoptosis in cancer cells, comparable to the FDA-approved photo-
dynamic therapy (PDT) drug Photofrin® [17-20].  Furthermore, the green emission of curcumin is used in 
cellular imaging [21]. 
Curcumin exists as keto-enol tautomers (Scheme 1), being present predominantly in the keto form in acidic 
and neutral solutions, with the enol tautomer exhibiting stability in alkaline media.  It is safe even at high 
doses [22,23], as shown in animal and human trials, but its effectiveness in clinical applications is limited 
due to low solubility, poor bioavailability in aqueous media,and hydrolytic instability under physiological 
conditions [24-26].  The main reasons for its poor bioavailability are low absorption, rapid metabolism, and 
fast systemic elimination from the biological system(s) [27].  Hence, despite its efficacy and safety, curcu-
min has not yet been granted approval as a therapeutic agent. 
Several methods have been applied to improve stability and bioavailability of curcumin, including a) addi-
tion of piperine as an adjuvant, in order to block the metabolic pathways of curcumin, b) encapsulation in 
nanoparticles, liposomes, micelles, or phospholipid complexes, c) concomitant administration of quercetin, 
lecithin, eugenol, genistein, terpinol, etc. [28], and d) addition of rubusoside [29], or complexation with 
phosphatidyl choline [30]. 
In view of the wide spectrum of pharmacological properties of curcumin [31,32] the investigation of its co-
ordination chemistry with metal ionsemerges as an appealing prospect that may render that physiological 
agent soluble and bioavailable, thus leading to its employment in diagnostic or therapeutic applications.  To 
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that end, it has been proven that complexation of curcumin to an oxophilic metal ion via the β-diketone moi-
ety renders curcumin hydrolytically stable [33-35]. 
Vanadium has been known to exhibit a wide spectrum of reactivities at the cellular level, with targets elicit-
ing interactions and/or interactions sought out in the framework of human (patho)physiologies [36].  From 
Diabetes mellitus to various forms of cancer, appropriate configuration of the vanadium coordination sphere 
led to its employment as a competent hybrid metallo-agent, ultimately delivering its biological potential 
[37,38].  In view of such reactivity on behalf of vanadium and the associated biological potential of curcu-
min as an antioxidant natural product, research was launched in our lab to probe into an appropriately con-
figured vanadium-curcumin assembly of complexing moieties, supported by ancillary ligands and collective-
ly giving rise to soluble, bioavailable and biologically competent vanado-materials of distinct bioprofile. 
To that end, the synthetic reactivity of the ternary system of V(IV) with curcumin and the ancillary aromatic 
chelator 2,2’-bipyridine (2,2’-bipy) was investigated in alcoholic media, ultimately leading to the isolation 
and physicochemical characterization of a crystalline ternary complex assembly.  To the best of our 
knowledge, it is the third ternary system crystallographically characterized with the VO2+ moiety, curcumin 
as the ligand, and an incorporated N,N-aromatic chelator [33].  The structural composition and nature of the 
newly arisen material prompted further investigation of its biological reactivity profile, thereby setting the 











Enol form Keto form  
Scheme 1: Keto-enol tautomers of curcumin. 
 
2. Experimental Section 
2.1 Materials and Methods.  All experiments were carried out under aerobic conditions.  The structures of 
the employed ligands are shown in Scheme 2.  The following starting materials were purchased from com-
mercial sources (Sigma, Fluka) and were used without further purification: curcumin, 2,2’-bipyridine (2,2’-
bipy), and vanadyl sulphate trihydrate (VOSO4·3H2O).  Solvents: methanol, diethylether.  The isolated and 







Curcumin 2,2'-bipyridyl  
Scheme 2: Schematic representation of the ligands used in this study. 
4 
2.1.1 Physical measurements.  FT-Infrared spectra were recorded on a Perkin Elmer 1760X FT-infrared 
spectrometer.  A ThermoFinnigan Flash EA 1112 CHNS elemental analyzer was used for the simultaneous 
determination of carbon, hydrogen, and nitrogen (%).  The analyzer operation is based on the dynamic flash 
combustion of the sample (at 1800 °C) followed by reduction, trapping, complete GC separation and detec-
tion of the products.  The instrument is a) fully automated and controlled by PC via the Eager 300 dedicated 
software, and b) capable of handling solid, liquid or gaseous substances.   
2.1.2 ESI-MS measurements.  The Electrospray Spray Ionization mass spectrum was obtained on an Ag-
ilent Technology LC/MSD trap SL instrument and Thermo Scientific, LTQ Orbitrap XL™ high resolution 
system. 
2.1.3 Solution NMR Spectroscopy.  Solution 1H- and 13C-NMR experiments for 1 were carried out on Var-
ian 600 MHz spectrometer.  The sample concentration was ~5 mM.  Freshly prepared material was dis-
solved in deuterated dimethyl sulfoxide (DMSO-d6).  The spectra were run 2h after complete dissolution of 
the sample.  Carbon spectra were acquired with 5000 transients, a spectral width of 37000 Hz and a relaxa-
tion delay of 2 s. Proton spectra were acquired with 128 transients and a spectral width of 9000 Hz.  Exper-
imental data were processed using VNMR routines. Spectra were zerofilled and subjected to exponential 
apodization prior to FT.  Chemical shifts (δ) are reported in ppm, while the spectra were referenced through 
the standard experimental setup. 
2.1.4 UV-Visible measurements.  UV-Visible (UV-Vis) measurements were carried out on a Hitachi U-
2001 spectrophotometer, in the range from 190 to 1000 nm. 
2.1.5 Fluorescence measurements.  Steady state fluorescence emission and excitation spectra were record-
ed on a Hitachi F-7000 fluorescence spectrophotometer from Hitachi High-Technologies Corporation.  The 
employed slit widths (em, ex) were 5.0 nm and the scan speed was 60 nm.min-1.  All measurements were 
carried out at room temperature.  The entire system was supported by the appropriate computer software, FL 
Solutions 2.1, running on Windows XP. 
2.1.6 Thermal studies.  A Perkin Elmer, Pyris 1, system was used to run the simultaneous Thermogravimet-
ric Analysis (TGA) experiments.  The instrument mass precision is 1 μg.  About 10 mg of compound 1 was 
placed in an open alumina sample pan for each experiment.  High purity air was used at a constant flow rate 
of 30 mL.min-1, depending on the conditions required for running the experiments.  During the experiments, 
the sample weight loss and rate of weight loss were recorded continuously under dynamic conditions, as a 
function of time or temperature, in the range 30–850 C.  Prior to activating the heating routine program, the 
entire system was purged with the appropriate gas for 10 min, at a rate of 30 mL .min-1, to ensure that the de-
sired environment had been established. 
2.1.7 Magnetization measurements.  Magnetization measurements on a 20.2 mg powder sample of 1were 
performed on a Quantum Design Vibrating Sample Magnetometer QD-Versalab in the 50–300 K tempera-
ture range and fields up to 3 T.  Measurements were corrected for the diamagnetic contribution of the sam-
ple holder and Teflon wrap, -3.1x10-10 emu.Oe-1, and the magnetic contribution of the brass half-tube sample 
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holder.  The diamagnetic contribution of the compound ions was not taken into account as it is ~7.4x10-4 
emu.mol-1 [39], five orders of magnitude lower than the experimental molar susceptibility, which is ~24 
emu.mol-1 at room temperature in a field of 10000 Oe. 
2.1.8 EPR measurements.  Continuous wave (cw)X-band Electron Paramagnetic Resonance (EPR) meas-
urements were performed on a Bruker ER 200D instrument, equipped with ESR-9Oxford cryostat and an 
Anritsu microwave frequency counter.  Pulse EPR measurements at X-band (mw frequency 9.710 GHz) 
were performed on a Bruker ESP 380E spectrometer, equipped with an EN 4118X-MD4 Bruker resonator. 
Measurements at cryogenic temperatures were performed using a helium cryostat from Oxford Inc. The mi-
crowave frequency was measured using a HP 5350B microwave frequency counter and the temperature was 
stabilized using an Oxford ITC4 temperature controller.  Hyperfine Sublevel Correlation (HYSCORE) spec-
troscopy with the pulse sequence π/2-τ-π/2-t1-π-t2-π/2-τ-echo was carried out with the following instrumental 
parameters: t/2 = 16 ns; starting values of the two variable times t1 and t2, 56 ns; time increment, Δt = 24 ns 
(data matrix 180 × 180).  In order to eliminate blind-spot artifacts, up to three spectra were recorded with τ = 
120, 144, and 168 ns.  A four-step phase cycle was used to remove undesired echoes.  The data were pro-
cessed with the program MATLAB (The MathWorks, Natick, MA).  The HYSCORE time traces were base-
line corrected with a second-order exponential, apodized with a Gaussian window, and zero filled.  After a 
two-dimensional Fourier transform the absolute-value spectra were calculated.  The experimental cw EPR 
and HYSCORE spectra were simulated using the EasySpin package [40]. 
2.1.9 DFT calculations.  The Vienna Ab Initio Simulation Package (VASP), version 5.3.3 [41], was em-
ployed in order to study the electronic structure of the title complex using Density Functional Theory (DFT).  
The Perdew-Burke-Ernzerhof (PBE) gradient-corrected exchange-correlation functional [42] was used along 
with the Grimme DFT-D2 method [43], in which van der Waals interactions are described via a pair-wise 
force field.  All calculations were performed using plane-wave basis sets, and the Projector Augmented 
Wave (PAW) method [44,45a], with a plane-wave cut-off energy of 400 eV. In addition, a Γ centered k-
point grid of 1×2×2 was employed for all calculations related to electronic structure, while geometry optimi-
zation involved a k-point grid of 1×1×1with maximum residual atomic forces of 0.01 eV∙Å-1.  Gaussian 
smearing with a width of 0.05 eV was used to determine how partial occupancies are set for each wave func-
tion.  The vanadium-curcumin complex was modeled using a simple monoclinic unit cell (Fig. S1) of di-
mensions a = 30.12 Å, b = 15.55 Å, c =15.94 Å, α = γ = 90°, and β=116.18°, with a unit-cell volume of 
6697.04 Å3; initial crystal structure and atomic coordinates were taken from the crystallographic data de-
scribed in section 3.2.  The Nudged Elastic Band (NEB) method was used to extract the interconversion ac-
tivation barrier between the cis- and trans-conformers in gas phase (Fig. S1).  Seven intermediate configura-
tions between cis- and trans- were created using an image dependent pair potential [45b], in which the max-
imum distance was set equal to 3 Å.  Illustrations of the computational structures in this work were con-
structed using the visualization tool VESTA [46]. 
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2.2 Synthesis  
2.2.1 Preparation of [VO(C21H19O6)(C10H8N2)(H2O)]2(SO4)
.2CH3OH
.3H2O (1).  To a solution of VO-
SO4·3H2O (0.22 g, 1.0 mmol) in 10 mL MeOH, curcumin (0.37 g, 1.0 mmol) was added under stirring.  The 
resulting brown solution was refluxed for two hours under continuous stirring and then cooled to room tem-
perature.  Subsequently, a solution of 2,2’-bipyridine (0.16 g, 1.0 mmol) in MeOH (5 mL) was added under 
continuous stirring.  The resulting clear, dark red reaction mixture was refluxed for an additional 2 h and 
then cooled to room temperature.  Subsequently, the reaction flask was placed at 4 oC and diethyl ether was 
added.  Two weeks later, a crimson-colored crystalline material precipitated at the bottom of the flask.  The 
product was isolated by filtration and dried in vacuo.  Yield: 0.60 g (83%).  Anal. Calcd for 1, 
[VO(C21H19O6)(C10H8N2)(H2O)]2(SO4)
.2CH3OH
.3H2O (1). (C64H72N4O25SV2, Mr1431.23): C, 53.71; H, 
5.07; N 3.91; S 2.24.  Found: C, 53.68; H, 5.03; N 3.84; S 2.22. 
2.3 X-ray crystal structure determination.  X-ray quality crystals of 1 were grown from a mixture of 
methanol-diethyl ether.  Crystals were taken from the mother liquor and mounted at room temperature on a 
Bruker Kappa APEX 2 diffractometer, equipped with a triumph monochromator, using Mo Kα radiation.  
Cell dimensions and crystal system determination were performed using 118 high θ reflections with 
I>10σ[I].  Data collection (φ- and ω-scans) and processing (cell refinement, data reduction and numerical 
absorption correction based on dimensions) were performed using the SAINT and SADABS programs 
[47,48].  The structure was solved through the SUPERFLIP package [49].  The CRYSTALS version 14.43 
program package was used for structure refinement by full-matrix least-squares methods on F2 and all sub-
sequently remaining calculations [50].  Molecular illustrations were drawn with the Diamond 3.1 crystallo-
graphic package [51].  All non-hydrogen atoms have been anisotropically refined.  All hydrogen atoms were 
found at their expected positions and were refined using proper riding constraints to the pivot atoms.  Crys-
tallographic details for 1are summarized in Table 1.  Further details on the crystallographic studies as well 
as atomic displacement parameters are given as Supporting Information and in the form of cif files. 
2.4 Biological studies 
Cytotoxicity is an important effect of new compounds, which must be taken into consideration when inves-
tigating living cells or tissues. It reflects the extent to which a chemical substance can damage an organism 
or a cell.  By extension, the term may be metaphorically used to describe toxic effects on various organelles, 
such as mitochondria, the nucleus, membranes, etc.  A comparative measure of compound effectiveness in 
inhibiting a specific biological or biochemical function is the half maximal inhibitory concentration (IC50).  
To this end, cytotoxicity of the newly synthesized compound 1 was investigated against one of the most in-
tensively studied eukaryotic model organisms, i.e. the fungal Saccharomyces cerevisiae (S. cerevisiae), by 
two methods: monitoring a) growth by turbidity, and b) viability by fluorimetry.  
2.4.1 Toxicity studies of curcumin and compound 1 against fungal yeast cells.  The lyophilized yeast 
cells were suspended in solution (0.2 mg.mL-1) in MMS medium (1.5% (w/v) glucose, 0.5% (w/v) NH4Cl, 
0.5% (w/v) K2HPO4, 0.1% (w/v) NaCl, 0.01% (w/v) MgSO4·7H2O, and 0.1% (w/v) yeast extract; the pH of 
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the medium was adjusted to 7.0) and were grown for 16 h in an incubator, at 30 oC under 200 rpm constant 
shaking.  The growth of the culture was monitored by measuring turbidity/absorbance at 600 nm on a Selec-
ta UV-2005 UV-Vis spectrophotometer.  To that end, cells were diluted with fresh MMS to obtain cultures 
of ~0.4 turbidity. The cells were then allowed to grow for 24 h at 30 oC under 200 rpm constant shaking, fol-
lowing exposure to curcumin, VO2+, 2,2’-bipy and the title compound 1, at several concentrations (2.5, 5, 
10, 15, 20, 25, 40, 50 μmol.L-1).  Dimethyl sulfoxide (DMSO) was used to dissolve-dilute both curcumin 
and 1, with its final concentration in the cultures maintained below 2% v/v.  Appropriate controls run on cul-
tures containing a final concentration of 2% DMSO did not show any appreciable toxicity.  Turbidity of the 
cultures was measured and graphed, as a function of substance concentration, to evaluate their effect on cell 
growth and determine the IC50 value.  Control cultures (in the presence of the respective DMSO concentra-
tion alone) were run to monitor the effect of DMSO on cell growth.  Cells from the respective cultures were 
harvested under centrifugation at 4,000 rpm for 5 min and then frozen, along with the extracellular media, 
for further analysis at -20oC. 
2.4.2 Determination of fungus viability.  In view of the fact that determination of toxicity through turbidity 
measurements may not be fully reliable for toxicity assessment, determination of cell viability was also car-
ried out.  The principle of the fluorescein diacetate (FDA) method in cell viability determination is based on 
a measurable difference between fluorescein released by live cells compared to that released by dead or stat-
ic cells due to toxicity, taking into consideration the fact that only live cells are able to hydrolyze FDA to 
fluorescein.  Yeast viability, in the absence and presence of various concentrations of curcumin and the title 
compound, was evaluated through determination of the degree of hydrolysis of FDA to fluorescein by S. 
cerevisiae culture cells.  FDA is hydrolyzed to fluorescein and acetic acid by different enzymes of the pri-
mary metabolism of fungi and micro-organisms, encompassing proteases, lipases, and esterases [52].  A 
stock solution of FDA in acetone (2 mg.mL-1) was added to reach a final concentration of 10 μg.mL−1 and 
the cultures were incubated at 37 oC on a rotary shaker (120 rpm) for a total of 1 h.  The reaction was termi-
nated by diluting the reaction mixture with one volume of acetone and the released fluorescein was meas-
ured on an F-7000 FL Spectrophotometer (excitation: 494.0 nm; emission: 500-560 nm). 
2.4.3 Lipid peroxidation by malondialdehyde determination. Quantification of lipid peroxidation is es-
sential to assessing oxidative stress induced in various abnormal pathophysiological cellular situations, e.g. 
exposure to various chemical agents.  One of the lipid peroxidation natural by-products forming is 
malondialdehyde (MDA), which is an endogenous genotoxic end-product of enzymatic and oxygen radical-
induced lipid peroxidation.  The MDA in the sample reacts with Thiobarbituric Acid (TBA) to generate the 
MDA-TBA adduct. The MDA-TBA adduct can be easily quantified colorimetrically (λ = 532 nm).  Increase 
of MDA levels suggests higher lipid peroxidation [53].  Cell cultures alone and exposed to various concen-
trations of either curcumin or 1 were collected and boiled for 15 min in a buffer containing 100 mM NaCl, 
1% (w/v) SDS, 2% (v/v) Triton X-100, 10 mM Tris-HCl pH 8.00, and 1 mM EDTA.  Then, the samples 
were lysed by ultrasound (15 s, 10 cycles).  Lysates were subsequently clarified by centrifugation (10,000 
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rpm for 15 min).  A volume of 500 μL of either lysates or culture growth medium were a) dissolved in a so-
lution containing 20% (w/v) trichloroacetic acid (TCA) and 0.67% (w/v) thiobarbituric acid (TBA), and b) 
boiled for 1 h.  After cooling to room temperature, the reaction mixtures were centrifuged and the absorb-
ance of the supernatant was measured at 532 nm to quantify the purple MDA-TBA product [54]. 
2.4.4 Oxidative stress by determination of Reactive Oxygen Species.  
The term Reactive Oxygen Species (ROS) pertains to all reactive molecules and free radicals originating 
from molecular oxygen.  The electronic structure of oxygen renders the molecule susceptible to radical for-
mation.  The generation of oxygen-based radicals, derived during the mitochondrial electron transport of 
aerobic respiration or redox enzymes and metal-catalyzed oxidation, leads to detrimental consequences.  Se-
quential reduction of oxygen through addition of electrons leads to the formation of many ROS species, in-
cluding superoxide ion, hydrogen peroxide, hydroxyl radical, hydroxyl ion, and nitric oxide.  It is also noted 
that ROS can serve as both intra- and inter-cellular messengers.  ROS generated intracellularly by S. cere-
visiae, as a response to the exposure to various concentrations of curcumin and the title vanadium com-
pound, were measured via the nitrobluetetrazolium chloride (NBT) reduction [54].  Fungal cells, collected 
from each of the previously mentioned cultures, were dispersed in 100 μL of MMS growth medium, and 500 
μL of 1 mg.mL-1NBT solution was added.  The reactions were run at 37 oC under shaking for 1 h and termi-
nated with 100 μL of 0.1 N HCl.  The mixtures were centrifuged at 1500 g for 10 min and the resulting pel-
lets were dispersed in 600 μL of DMSO to dissolve the formazan product.  Subsequently, 500 μL of MMS 
was added, the mixtures were centrifuged once again, and the absorbance of the supernatant derived from 
cell lysis was measured (intracellular ROS) at 575 nm, whereas the blue color of the supernatant (extracellu-
lar ROS) was measured at the same wavelength. 
2.4.5 In vitro interaction experiments of curcumin and 1on eukaryotic or bacterial DNA. DNA interac-
tions (cleavage/binding reactivity) with the title compounds was monitored following incubation of the latter 
with dsCTDNA or plasmid pUC18, followed by separation of the derived products using agarose gel elec-
trophoresis.  Specifically, the pDNA cleavage efficiency of these compounds was measured by determining 
their ability to convert the supercoiled (SC) or relaxed form (R) of pDNA to the nicked circular (NC) or/and 
linear form.  Plasmid DNA preparation appears in two conformations: the supercoiled and open-circular 
forms.  Given the presence of a break in only one of the strands in the latter species, DNA will remain circu-
lar, however, the strand break permits rotation around the phosphodiester backbone thus releasing the super-
coils.  Consequently, for the same DNA, the supercoiled conformation runs faster than the open-circular 
form.  If DNA sustains double strand breaks, it produces a linear conformation.   Linear DNA runs through a 
gel end first and thus involves less friction than open-circular DNA, yet more than supercoiled DNA, there-
by migrating at a rate intermediate between the two. 
For DNA damage experiments, native DNA (double-stranded DNA) (CT-dsDNA) type I, highly polymer-
ized, from calf thymus glands, was purchased from Sigma (D-1501). Plasmid DNA, (pDNA) (pUC18) was 
isolated from Escherichia coli (Top 10) using the GenEluteTM HP endotoxin-free plasmid maxiprep prepa-
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ration (Sigma–Aldrich), according to manufacturer specifications.  The DNA stock solution (1 mg.mL-1) was 
prepared at 0–4 oC by dissolving the commercially purchased calf thymus DNA in buffer A (50 mMTris 
((hydroxymethyl)amino methane)–HCl buffer (pH 7.5)).  Agarose and the intercalating dye ethidium bro-
mide (EtBr) were purchased from Invitrogen and Sigma, respectively.  
Calf thymus double-stranded DNA (CT-dsDNA) was exposed to several concentrations of curcumin or 1, at 
a constant temperature of 37 oC for 1 h, in buffer A, to a final volume of 20 μL, and the interaction products 
were separated using agarose gel electrophoresis.  Reactions, containing aliquots of 3 μg of nucleic acid 
(dsCT-DNA) and various concentrations of curcumin or 1 after incubation, were terminated by adding 5 μL 
loading buffer, consisting of 0.25% w/v bromophenol blue and 30% v/v glycerol in water.  The products re-
sulting from interactions of curcumin and 1 with DNA were separated by electrophoresis on agarose gels 
(1% w/v), containing 1 μg.mL-1 EtBr in 40.10-3 M Tris–acetate, pH 7.5, 2.10-2 M sodium acetate, 2.10-3 M 
Na2EDTA, at 5 V
.cm-1. Agarose gel electrophoresis was run in a horizontal gel apparatus (Mini-SubTM 
DNA Cell, BioRad) for about 4 h.  The gels were visualized under a UV illuminator, following staining with 
the fluorescence dye ethidium bromide due to its intercalation into the double stranded DNA. 
2.4.6 Statistical analyses.  Origin Pro 9.0 (Origin Lab Corporation) was employed for the statistical analysis 
and graph construction.  Results are presented as means (SEMs), with standard deviation (SD) depicted as 
error bars and the experiments having been run as triplicates.  One-way analysis of variance (ANOVA) test 
was used for discriminating between groups tested.  For statistical significance to be reached (ns, p>0.05), a 
value of p˂0.05 (*) was pre-requisite, with p<0.1 (**) and p<0.001 (***).      
3. Results  
3.1 Synthesis.  The synthetic exploration of the ternary V(IV)-curcumin-(2,2’-bipy) system in this work fol-
lowed carefully designed approaches.  To that end, the 
[VO(C21H19O6)(C10H8N2)(H2O)]2(SO4)
.2CH3OH
.3H2O (1) material was synthesized in a facile fashion 
from simple reagents in alcoholic solution.  In a typical reaction, VOSO4·3H2O reacted with curcumin using 
methanol as a solvent.  The overall stoichiometric reaction leading to 1 is shown schematically below: 
2VOSO4
.3H2O   +   2C21H20O6   +   2C10H8N2   +   2 CH3OH
[VO(C21H19O6)(C10H8N2)(H2O)]2(SO4)
.2CH3OH
.3H2O   +   H2SO4   +   H2O
 
Diethyl ether was added as a precipitating solvent to the reaction mixture.  A crimson-colored crystalline 
material emerged in the reaction described above, the analytical composition of which was consistent with 
the formulation in 1 (vide supra).  Positive identification of the crystalline product was achieved by ele-
mental analysis, FT-IR spectroscopy and X-ray crystallographic determination for isolated single crystals 
from 1 (vide infra).  The complex is stable in the crystalline form, in the air, for fairly long periods of time.  
It is readily dissolved in methanol, DMSO, and DMF, moderately soluble in water and ethanol, and insolu-
ble in acetone, acetonitrile, and dichloromethane at room temperature.   
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The scarcity of crystallographically characterized metal complexes of curcumin is also proved by relevant 
literature surveys that yielded ca. 150 publications in which only 13 crystal structures of such complexes are 
reported [55].  A summary of previous scientific works on the synthetic procedures of the crystallographical-
ly characterized curcumin complexes is presented in Table 2. 
 



























VO(ClO4)3 1,10-phenanthroline Et3N CH3CN/EtOH 1:1 1:1 1:1 
Slow evaporation of 
the complex in 
acetonitrile at room 
temperature 
33,56 
VO(ClO4)3 dipicolylamine Et3N CH3CN/EtOH 1:1 1:1 1:1 
Vapor diffusion of 
diethyl ether into 




Zn(O2CCH3)2(H2O)2 - - DMA/EtOH 1:1.8 - - 
Heating in a closed 
vessel at 75 oC 
58 
C6H5B(OH)2 - - CH2Cl2 1:1.17 - - 
Slow evaporation of 
the complex in 





Et3N CH2Cl2 1:1 1:1 1:1 







Et3N Acetone 1:1 1:1 1:1 
Slow evaporation at 
room temperature 
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Until 
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Slow evaporation of 
a solution of the 








Et3N MeOH 1:1 1:1 
Until 
pH 7.5 
Slow evaporation of 
a solution of the 




[(p-cymene)RuCl2]2 - NaOMe MeOH ½:1 - ½:1 
Recrystallization in 
CHCl3 and slow 
evaporation at 4 °C 
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[(η6-p-Cymol)RuC12]2 - NaOH MeOH 1:1 - 1:1.5 
Slow evaporation of 








triphenylphosphine - MeOH 1:1 1:2 - 








KOH MeOH 0.5:1 0.5:1 0.5:1 
Recrystallization 
from a mixture of 
dichloromethane 
and n-hexane and 






KOH MeOH 0.5:1 0.5:1 0.5:1 
Recrystallization 
from a mixture of 
dichloromethane 
and n-hexane and 





3.2 Description of X-ray Crystallographic Structure 
The X-ray crystal structure of 1 reveals a discrete solid state lattice.  The structure of the vanadium assembly 
in 1 is shown in Fig.1.  Selected bond distances and angles are listed in Table 3.  Compound 1 crystallizes in 
the monoclinic space group C2/c. The asymmetric unit contains one singly cationicV(IV) complex assem-
bly, a one half sulfate dianion, one and half lattice water molecules and one lattice methanol molecule. The 
structure of 1 shows an oxidovanadium(IV) moiety, bound to the chelating N,N-donor 2,2’-bipy, O,O-donor 
singly anionic curcumin and one water molecule, thus giving rise to a VIVN2O4 coordination sphere in a dis-
torted octahedral geometry.  The V-N and V-O (curcumin) distances are in the range of 2.081(2) to 2.128(2) 
Å, and 1.956(2) to 1.964(2) Å, respectively.  The equatorial plane, arising from the coordinated atoms, orig-
inates in the N,N-donor and O,O-donor ligands, with the axial positions being occupied by the oxidovanadi-
um(IV) oxygen atom and the coordinated water molecule.  The V=O bond distance is 1.587(2) Å.  The V-O 
bond trans to the V=O group is long (2.308(2) Å), indicatingthattheV-OH2 bond could readily dissociate in 
solution as also suggested by ESI-MS (vide infra).The V-N and V=O distances were found to be consistent 
with those reported in the literature [33,66].  Seven hydrogen bonding interactions were found (Table S1) to 
contribute to a three dimensional (3D) crystal lattice.  Of the curcumin phenolic hydrogen atoms, the first 
one interacts with the oxygen atom from a neighboring oxidovanadium(IV) moiety and the second one with 
an oxygen atom from the sulfate anion. All four oxygen atoms from the sulfuric acid anion as well as the 
lattice water molecules bridge the lattice methanol molecule and the coordinated water ligand, thus forming 
a strong hydrogen-bonding network. The lattice can best be described as one assembled through parallel 
complex equatorial plane moieties in layers, connected with hydrogen-bonding interactions through the co-
ordinated water, oxidovanadium and sulfate anion oxygen atoms.  
3.3 FT-IR spectroscopy.  The FT-IR spectrum of 1 shows three bands at 1596 cm-1, 1508 cm-1 and 993 cm-
1, which can be attributed to the C=O, C=C (β-diketonate) and V=O stretching vibrations.  The bands ap-
pearing in the 667-768 cm-1 range and at 1030 cm-1are attributed to the V-O stretching mode [67].  The band 
at 470 cm-1 corresponds to the V-N bond [68].  The frequencies of the observed vibrations were shifted to 
lower values, in comparison to the corresponding vibrations in free curcumin, thus indicating changes in the 
vibrational status of curcumin upon binding to the V(IV) ion.  All observations were further attested to by 
the X-ray crystal structure of 1. 
3.4 ESI-MS studies.  The high resolution ESI-MS of 1 in H2O showed a peak corresponding to the [M-H-
2O]
+ (Fig. 2).  The mass spectral data and the associated simulations suggest the presence of the complex 
species [VO(C21H19O6)(C10H8N2)]
+. 
3.5 Solution NMR spectroscopy.  The room temperature 1H-NMRand 13C-NMR spectra of 1in DMSO-d6 
(Fig. 3A-3B) showed characteristic spectral features of the metal-bound bipyridine ligand and the β-
diketonato moiety.  The signals in the 1H-NMR spectrum are in agreement with a 1:1:1 metal:(N,N-
ligand):curcumin stoichiometry [69].  The spectra are not identical with those of free bipy and curcumin in 
the same solvent and under identical experimental conditions, indicating a) the significant influence of the 
paramagnetic center on the ligands upon coordination, and b) formulation of the identity of 1 in solution 
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[69,70].  The signals from the aromatic protons (h, i) and (b) as well as the olefinic proton (f) coalesce in the 
1H-NMR spectrum of 1, as do the signals from the aromatic proton (j) and the olefinic proton (g).  Moreo-
ver, the phenolic proton (k) exhibited a broad feature in comparison to literature reported 1H-NMR spectra 
of free curcumin [71-73].  No significant shifts were observed for the protons compared to free curcumin 
and 2,2’-bipy, respectively.  The spectrum in (A) indicatively shows the peak (marked as e) at ~5.9 ppm, 
corresponding to the C-H proton of the β-diketone moiety.  Its relatively low intensity is due to the pro-
longed retention of the compound in solution [33].  In the case of the 13C-NMR spectrum of 1, no signal was 
observed for the two carbonyl carbons (C-6) and no significant shifts were observed for all carbons in com-
parison to free curcumin and 2,2’-bipy.  However, the intensity of the signals was significantly reduced 
compared to that of unbound curcumin and 2,2’-bipy [61-63]. 
3.6 UV-Vis spectroscopy.  The UV–Vis spectra of pure curcumin and 1 were recorded in methanol at a 
concentration of 10-6 M (Fig. 4A).  Free curcumin exhibits an absorption maximum at 430 nm and a weak 
absorption band at 278 nm.  The maximum absorption is assigned to the π–π* transitions in the enolic form 
in solution [74,75].  A shift in the observed absorption maximum [76-80], is linked to the ionization of the 
phenolic OH group, leading to a bright red-colored phenoxide moiety [75,81-83].  In view of the aforemen-
tioned curcumin features, the electronic spectrum of 1 exhibits a similar pattern with the spectrum of curcu-
min, involving an intense absorption maximum at 446 nm (λmax, ε~138,000 Μ
-1.cm-1), and an absorption 
band at 279 nm (ε~109,000 Μ-1.cm-1).  The observed bathochromic shift in the intense absorption for 1, 
compared to free curcumin, is indicative of its extended conjugation and coordination to the metal center 
[84-88].  Fig. 4B presents the electronic d-d transitions of 1 at lower energies and at concentrations higher 
than 10-6 M.  The d-d band appears as a shoulder at around 300 nm upon increase in the concentration of 1. 
3.7 Fluorescence studies.  Steady state fluorescence measurements of emission and excitation spectra of 
pure curcumin and 1 were recorded in methanol, at a concentration of 10-6 M and at room temperature (Fig. 
5).  The results at hand suggest that free curcumin exhibits an emission with a single broad band around 537 
nm, when excited at 372 nm, which could be attributed to aromatic π−π* transitions.  The broadening of the 
spectrum is assigned to the methanol interactions with the enolic protons of the keto-enol moiety [89].  The 
emission spectrum of 1 shows a quenched single broad band with an emission maximum at 539 nm, when 
excited at 405 nm, which could be attributed to aromatic π−π* transitions.  The observed quenching, com-
pared to the free ligand, could be attributed to the ligand coordination effect reflected into the presence of 
the deprotonated curcuminato ligand bound to V(IV).  This fact is common in paramagnetic metal centers 
that normally act as quenchers, displaying chelation enhancement of quenching (CHEQ) effects [90,91]. 
3.8 Thermal studies.  The thermal decomposition of 1 was studied by TGA under an atmosphere of air 
(Fig. 6).  Compound 1 is thermally stable up to 44 C.  From that point on, a fairly broad heat process points 
to the dehydration and solvent removalof 1, with the release of moisture and lattice water and methanol mol-
ecules between 44 oC and 232 oC.  In fact, a 9.3% drop in weight, from the start of the thermal treatment un-
til 108 oC, is consistent with the release of the two methanol and three water molecules in the lattice, along 
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with the sole water molecule in the coordination sphere of vanadium, consistent with the theoretically ex-
pected value of 9.5%.  Between 232 oC and 454 oC, further weight loss is observed, in line with the decom-
position of the organic structure of the molecule.  No clear plateaus are reached in this temperature range, 
suggesting that the arising products are unstable and decompose further.  A plateau in the decomposition of 
1 is reached at 454 C, with no further loss up to 700 C, in line with the thesis that the product at that tem-
perature and beyond (700 C) is V2O5.  The violent reaction observed at around 728 
oC, not associated with 
mass loss,may be related to a crystalline structural change [92], or the melting of the product of the thermal 
decomposition reaction, V2O5.  The total weight loss of ~87.4% is in agreement with the theoretical value 
~87.4%, according to the following equation: 
 
Examination of the residue by Scanning Electron Microscopy (SEM) (Fig. S2) and powder XRD showed the 
presence of oxides, ordinarily obtained under oxidative conditions, and consistent with previously reported 
results of TGA on vanadium-containing species [93,94]. 
3.9 Magnetization measurements.  The temperature dependence of the effective magnetic moment μeff and 
μeff*T of 1 in a field of μ0H = 1 T (10000 Oe) is shown in Fig. 7.  Magnetic susceptibility is paramagnetic, 
inversely proportional to temperature.  Fitting the molar magnetic susceptibility to the Curie law, 
χmol = Cmol/T 
the molar Curie constant Cmol = 0.686 cm
3·K·mol-1 (8.62 x 10-6 m3·K·mol-1) is obtained.  
The paramagnetic effective magnetic moment μeff is deduced from  
Cmol = NAVg
22S(S+1)/3kB 
where β is the Bohr magneton, N is Avogadro’s number, g is the Landé factor, and kB is the Boltzmann con-
stant.  Taking into account that there are two vanadium atoms per formula unit, the experimental effective 
magnetic moment is 1.69 μΒ.  The theoretical effective moment is μeff=1.55 μΒ, in line with the equation 
μeff = g[J(J+1)]
1/2μΒ 
where J is the total angular momentum quantum number, and g the Landé factor, of an isolated V(IV) 
[Ar]3d1 ion,with a total spin quantum number S=1/2, and total angular momentum quantum number L=2 
(J=L-S=3/2 and g=0.8).  In oxidovanadium(IV) complexes, the crystal field of surrounding ions quenches 
the angular momentum (L=0, J=S and g=2) [95-97], so that the theoretical spin-only magnetic moment is 
μeff= 1.73 μΒ, with V(V) [Ar]3d
0 exhibiting a zero spin moment.  The experimental magnetic moment of va-
nadium in 1 is quite close to the theoretical spin-only value of V(IV), μeff =1.73 μΒ, indicating that the oxida-
tion state is 4+ [98]. 
3.10 EPR studies.  The CW-EPR spectrum of 1 in a methanol/toluene (1:1) frozen solution, recorded at 70 
K, is shown in Fig. 8.  The spectrum is consistent with a mononuclear vanadyl species and can be simulated 
with the following spin Hamiltonian: 
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H = SgB + IAVS 
where S = 1/2, the electronic spin,  is the Bohr magneton, B is the external magnetic field, I =7/2 is the nu-
clear spin of the 51V nucleus, and AV is the hyperfine interaction tensor.  The experimental spectrum is re-
produced with the following parameters: 
gx=1.979(1), gy=1.978(4), gz = 1.940(6), A
V




z = 506 MHz. 
Moreover, in order to a) reveal weak hyperfine couplings with ligand atoms participating in the coordination 
sphere of vanadium, and b) gain further insight into the electronic structure and coordination mode of the 
ligands in 1, HYSCORE experiments were carried out at 40 K [99].  The relevant spectra are shown in 
Fig.9A-C.  Specifically, the HYSCORE spectrum reveals several correlation peaks, both in the left and right 
quadrant.  The cross-peaks at (-9,5) and (-5,9) MHz are separated by approximately four times the nuclear 
Zeeman frequency of 14N, 4ν14N = 4 MHz.  In that respect, they are assigned to a strongly-coupled nitrogen 
atom with a hyperfine coupling A  6.5 MHz.  A successful simulation is obtained assuming two nitrogen 
atoms with identical principal axis system (PAS) parameters shown in Table 4. The isotropic hyperfine in-
teraction (HFI) aiso = -6.3 MHz and the nuclear quadrupole coupling constant K = e
2qQ/4h, with the asym-
metry parameter η = (Qx–Qy)/Qz, are typical for equatorially coordinated nitrogen atoms in [V
IVO]2+ vanadyl 
complexes [100].  The simulation reproduces well both the shapes and relative intensities of most correlation 
peaks.  However, the strong peaks in the right quadrant, marked by arrows in Fig.9A, cannot be obtained 
with these parameters, since they correspond to a weakly-coupled nitrogen atom with a hyperfine coupling 
A<2ν14N.  Fig.9C shows the simulation using the previous parameters for the strongly-coupled nitrogen at-
om, but now a smaller coupling with aiso = 0.9 MHz is assumed for the second nitrogen (Table 5). The latter 
hyperfine coupling is in line with axially coordinated nitrogen atoms in vanadyl complexes [101]. 
Comparing the experimental spectrum of Fig. 9A with the simulations of Figs. 9B and 9C, it is clear that the 
parameters in “set 2” reproduce satisfactorily all correlation peaks.  Therefore, based on the HYSCORE 
analysis, it is concluded that in solution, one of the 2,2’-bipynitrogen atoms occupies an axial position, re-
linquishing its place to equatorial coordination with a water or solvent molecule.  This effect is well-known 
for vanadyl complexes and has been verified with ESEEM experiments in the past [102].  It is worth noting, 
however, that a mixture of both species (set 1 and set 2) cannot be excluded at this juncture, as the sum of 
their corresponding simulation spectra (B and C with an approximate 1:1 contribution) would still reproduce 
well all features of the experimental HYSCORE spectrum (vide infra). 
3.11 DFT calculations.  In order to look closely at the electronic structure of the vanadium-curcumin com-
plex, DFT calculations were performed following the procedure described in section 2.1.9.  The total density 
of states (DOS) as well as the projected density of states from individual contributions of V, O, C, N, S, and 
H atoms of the complex is shown in Fig.10A. The Fermi level (0 eV) is found to be located at ~0.2 eV 
above the conduction band minimum, which displays a major contribution from V3d orbitals and a small 
hybridization with O and C2p orbitals.  To further investigate the origin of these states, their corresponding 
partial charge density was plottedin Fig.10B, showing that charge density being strongly localized on the V 
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atom, with moderate localization on the surrounding O, C, and N atoms. This provides evidence that the va-
nadium ion acts as the coordination center, while oxygen, carbon and nitrogen atoms constitute part of the 
surrounding ligand environment.  In order to quantify this picture, net charge analysis [103] was performed 
to locate charge transfer occurring within the coordination assembly.  It appears that, on average, there is a 
depletion of charge of ~1.00 |e| from the O7, ~0.84 |e from the O1 and O2, and ~0.75 |e| from the O31 at-
oms. In addition, charge depletion of ~1.12 |e| is observed from the N1 and N2 atoms.  Finally, charge trans-
fer of ~1.02 |e| is observed, on average, from the ligand toward the coordination center, i.e. the vanadium 
atoms, giving rise to the appearance of filled 3d vanadium states at the conduction band edge (Fig.10A), as 
experimentally attested to through UV-Vis spectroscopy (vide supra).  
EPR measurements performed on the sample (Section 3.10) suggest two potential conformers present in so-
lution, i.e. a trans- and a cis- (Fig. S1B) (vide supra).  DFT calculations, using the Nudged Elastic Band 
method (Section 2.1.9), were performed to gain insight, in terms of a potential interconversion process, by 
extracting the energy activation barrier required for the conformational change from the trans- to cis- con-
former and vice versa.  As observed in Fig. 11, the total energy of the trans-conformer is 0.14 eV higher 
than the cis conformer, thus indicating that the latter species is most stable energetically.  In addition, the 
activation barrier required for the interconversion from trans- to cis-conformer is found to be 0.25 eV, while 
the activation barrier for the opposite process, i.e. interconversion from cis- to trans-, is found to be 0.39 eV.  
This is an indication that conversion from trans- to cis-conformer is favorable, a finding consistent with the 
state of a rising (upon dissolution of 1) equilibrium toward the cis conformer as suggested via EPR meas-
urements (vide infra). 
3.12 Toxicity of the compounds against fungal yeast cells.  For the investigation of potential toxicity ef-
fects of both natural curcumin and the newly synthesized compound 1, yeast cells were grown in the pres-
ence of various concentrations of each substance.  Control cultures were also prepared in the absence of cur-
cumin and 1.  Inhibition of cell growth and toxicity of these compounds was determined by measuring both 
culture turbidity and viability through metabolic enzymatic activity compared to control cultures.  As can be 
seen in Fig. 12, growth of cultures is inhibited gradually in a concentration-dependent manner, in both cases.  
The observed inhibition reached ~15% in the presence of the highest concentration of curcumin (50 μΜ, 
p<0.05) compared to the control culture, but it was more pronounced in cultures grown in the presence of 1, 
approaching 50% for the same concentration (p<0.05).  The results afforded an IC50 value of >100 μΜ for 
curcumin, with the IC50 value of 1 being lower (53±3 μΜ), but still high.  Fungal growth after treatment with 
solely 2% (v/v) DMSO did not inhibit growth significantly (10±4%, p>0.05).  Control studies for pure VO-
SO4 and 2,2´-bipy were also conducted (Fig. S3).  No significant toxicity changes were noticed in the pres-
ence of either compound.  
3.13 Fungal cell viability. Yeast cell viability fell to 50% compared to the control, in the presence of 10 μM 
curcumin, whereas for a similar effect, a concentration of 20 μMof 1was required.  Thus, the calculated IC50 
value of fungal cell viability for 1 is equal to 20±2 μΜ in comparison to pure curcumin (10±1).It can be 
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concluded that a concentration of up to 10 μΜ of 1 could be considered non-toxic, as no more than a 10% 
drop in growth or viability was observed, whereas the same concentrations of pure curcumin seem to disturb 
the metabolic activity of the cells.  Taking into consideration the fungal growth experiment, it came as a sur-
prise, however, from the viability experiments, that the enzymatic potential of cells toward FDA-hydrolysis 
is lower (or defective) in curcumin-treated than in compound 1-treated yeast cells, at almost all concentra-
tions tested, a fact reflected in a pattern of two parallel curves (Fig. 13A).  At concentrations higher than 25 
μΜ, cell viability remained at 20% and 10% levels compared to control cultures in the presence of curcumin 
and 1, respectively. It should also be noted that part of the inhibition observed at such high concentrations of 
both curcumin and 1 may be attributed to the presence of the employed DMSO in the cell cultures (data not 
shown).  A representative figure (Fig. 13B) of cell viability shows the emission intensity curves of S. cere-
visiae cells exposed to 5 μΜ and 25 μΜ of curcumin and 1, compared to non-exposed cells, as a function of 
the excitation wavelengths.  Obviously, the viability of S. cerevisiae cells exposed to 5 μΜ of 1 is higher 
than that of curcumin for the same concentration and in both cases lower than that of the non-exposed fungal 
cells. 
3.14 Oxidative stress studies. Curcumin is a well-referenced anti-oxidant compound.  Therefore, a main 
target of this study was to a) initially verify previous results on the anti-oxidant activity of curcumin-based 
compounds, and b) ultimately investigate the anti-oxidant potential of the newly-synthesized compound 1.  
Two major markers of oxidative stress were studied: MDA – a product of lipid peroxidation, and ROS pro-
duction.  
3.14.1 Lipid peroxidation through MDA Determination 
Lipid peroxidation was indirectly measured by monitoring MDA production in the presence of cell cultures, 
as a result of the exposure to curcumin and 1.  MDA levels compared to control (and control containing 2% 
DMSO) are presented for various concentrations of curcumin and 1, as measured in cell lysates (intracellular 
MDA) and growth medium (extracellular MDA), respectively. Fungal cells exposed to either curcumin or 1, 
in the concentration range 5-25 μM, caused reduction of intracellular MDA levels (up to ~25%) compared to 
control.  This result may strongly support the notion that cells exposed to curcumin or 1 (at low concentra-
tions up to 25 μΜ) amplifies cellular protection intracellularly against lipid peroxidation by lowering MDA 
levels ~15% compared to control cells.  Interesting enough was the observation that MDA levels, produced 
by fungal cells intracellularly at the highest concentrations (40 and 50 μM), were higher in curcumin-
exposed cells than in cells exposed to 1.  Specifically, in curcumin-exposed cells, MDA levels, at the respec-
tive concentrations, reached 160% and 207% of the control, respectively, thus revealing that 1 is able to sig-
nificantly reduce (abolish) MDA levels generated by curcumin alone.  In conjunction with that result, it is 
important that in the case of cells exposed to 1 at high concentrations (40 and 50 μM), MDA levels seem to 
be maintained close to control levels (Fig. 14A).  On the contrary, extracellular MDA levels of fungal cells 
exposed to curcumin and 1 increased gradually in a concentration-dependent manner (from 10 to 50 
μΜ),reaching a maximum value of 170% compared to control, whereas in fungal cells exposed to 1 extracel-
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lular MDA levels remained at control levels until 10 μM, subsequently increasing at higher concentrations to 
250%.  Specifically, when fungal cells are exposed to concentrations higher than 15 μM, the extracellular 
MDA levels are higher in the case of 1 compared to curcumin for the same concentrations (Fig. 14B).  In 
conclusion, to justify this result and taking into consideration the results obtained from the intracellular 
MDA levels, it appears that 1 seems to be a more potent chemo-protective agent against harmful MDA than 
curcumin under the experimental conditions and the model organism employed.  The behavior indicates a 
cell protection mechanism, whereby various toxic agents are exported from the cell interior, as MDA levels 
were found to increase in the extracellular medium. 
Experiments were also carried out for VOSO4 and 2,2´-bipy.  Interestingly, both of these compounds bear a 
significant, yet opposite effect, on both intracellular and extracellular levels of MDA.  A 10 μΜ concentra-
tion of 2,2´-bipy raised extracellular MDA levels up to 119% compared to control, an effect that dwindled 
gradually, amounting to an 88% drop of MDA levels, when 50 μΜ of 2,2´-bipy was used.  Increasing VO-
SO4 concentration caused a commensurate drop of extracellular MDA levels, up to 73% at 50μΜ (Fig. S4).  
When intracellular MDA levers were assessed, however, there was a profound decrease of their levels when 
2,2´-bipy concentration rose (up to 21% at 40 and 50 μΜ) and a profound increase when VOSO4 levels rose 
(up to 333% at 25 μΜ) (Fig.S5).  It is, thus, obvious that it is rather difficult to explain the effect of com-
pound 1on MDA levels, as MDA by-products may be gradually released as a result of the metabolic activity 
of the yeast cells and they induce different effects on the oxidative status of lipids. 
3.14.2 ROS generation  
ROS generated continuously during aerobic metabolism are highly reactive molecules.  When in excess, 
they can lead to protein and DNA oxidation, protein cross-linking, and cell death.  Oxidative stress-induced 
damage, resulting from excessive accumulation of ROS within cells and/or their release into the culture me-
dia, is highly cell type-specific, and there is a difference in the capacity of various cell types to produce 
and/or release ROS in response to the same stimulus.  Although cells that produce and accumulate large 
amount of ROS within themselves can have detrimental effects on their own survival, the cells that are able 
to release a large amount of ROS extracellularly can cause damage to other cells.  ROS are unstable and 
have a short life in the extracellular medium.  In that respect, the antioxidant potential of curcumin and com-
pound 1 was evaluated in terms of either intracellular ROS generation or scavenging by the fungal S. cere-
visiae cells exposed to them.  It is noteworthy that 1, at low concentrations, attenuates oxidative stress intra-
cellularly in fungal cells exposed to it, reflected in the decrease of O2
−• in the fungal cytoplasm, reaching as 
low as 10%, with curcumin reaching 62%, compared to control (for 25 μΜ).This effect of 1occurred by 
lowering the levels of intracellular ROS more drastically compared to those of the parent curcumin.  Even 
minimal quantities of 1 (2.5 μΜ) could lower ROS levels to 22%, whereas the corresponding drop in the 
case of curcumin was 40%, compared to control. For all concentrations studied, compound 1 exhibited far 
better ROS-scavenging ability in comparison to curcumin.  When fungal cells were treated with curcumin, 
lower ROS levels (42.5% compared to control) were observed at a concentration of 2.5 μΜ.  ROS levels, as 
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a response to exposure of fungal cells to 10 μΜ and 50 μM curcumin alone, increased to 145%and 207%, 
respectively.  In contrast to that, a 10 μΜ concentration of compound 1 lowered ROS to 30%. When the 
concentration of 1 was raised to50 μΜ, a reduction of the ROS levels compared to pure curcumin (207%) 
took place down to the control level (100%) (Fig. 15).  Moreover, VOSO4 and 2,2´-bipy are both inducers of 
oxidative stress, as they induced an increase of ROS levels up to 124% and 123%, respectively, at a concen-
tration of 50 μΜ (Fig. S6).Thus, the anti-oxidant potential of 1 can be noted based on ROS-lowering activity 
reflecting measured ROS radical levels. 
3.15 In vitro effect of curcumin and compound 1 on DNA. One of the most significant targets in the de-
sign and use of several anticancer drugs is DNA and the investigation of their interaction with it.  There is 
plenty of biological and biochemical evidence on the existence of MDA contribution to DNA damage or 
MDA-induced DNA interstrand cross-links that a) could result from endogenous oxidative stress, and b) 
likely have biological effects on human cell physiology-pathology [104]. 
To probe potential DNA interactions (binding and/or damage) with 1, treatment of CT-dsDNA was investi-
gated at various concentrations of both curcumin and 1.  The treatment in both cases led to a concentration-
dependent DNA degradation, as deduced by a) quantitation of the decrease (~65%) of the intensity of the 
main DNA band integrity for the highest concentration of curcumin tested (50 μΜ) (Fig. 16A, lane 8), and 
b) the extent of band smearing.  The decrease was more pronounced at all concentrations tested in the pres-
ence of 1 (Fig. 16A, lanes 1´-8´) compared to control and curcumin alone (Fig. 16A, lane 1-8), and reached 
~73% in the presence of 50 μΜ(Fig. 16A, lane 8´), reflecting reduction of intensity, until the disappearance 
of the main DNA band.  The effects on DNA were summarized and plotted in Fig. 16B.  As a comparison, it 
is noted that loss of 50% DNA integrity was caused by 15 μΜ of compound 1, whereas the same result oc-
curred at 25 μΜ of curcumin.  
In addition, plasmid DNA (pDNA)(containing both supercoiled S and relaxed R forms) was treated with 
various concentrations of curcumin or 1 and the products were separated by agarose gel electrophoresis in 
mobility shift experiments. In both cases, an up-shift of pDNA was observed, exhibiting delayed electropho-
retic mobility, due to compound binding, thus resulting in aggregated or multimeric DNA forms remaining 
in the wells and being unable to enter the gel. More interesting was the observation that incubation with 1 
led to the degradation of the supercoiled DNA band (S) compared to control and curcumin alone (disappear-
ance of the respective band) at low concentrations (Fig. 16C, lanes 1´-4´),whereas at higher concentrations, 
formation of a new band emerged that was barely visible.  The latter species exhibited delayed electropho-
retic mobility compared to both pDNA bands, likely reflecting the presence of pDNA dimer (D) or multimer 
(M) forms as a result of the title complex interaction(s) (Fig. 16C, lanes 6´-7´).  Finally, attenuation of the 
intensity of all DNA bands occurred due to degradation (Fig. 16C, lanes 7´) compared to control.  The ob-
served differential behavior of interaction mode of both compounds with a) CT-dsDNA, causing gradual 
concentration-dependent degradation, and b) pDNA, causing aggregation rather than degradation, might be 
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attributed to the difference of the secondary and supercoiled structures of pDNA, being differentially acces-
sible for facile intercalation as in CT-dsDNA, thereby pointing toward an intercalating mode of action.   
4. Discussion 
4.1 Synthetic challenges in ternary metal-curcumin systems 
The bioactivity of physiological substrates of natural origin depends to a great extent on their a) structure, b) 
solubility and bioavailability, and c) chemical reactivity at the biochemical level.  Among such well-known 
physiological organic substrates, currently under investigation, curcumin emerges as a primary target of 
pharmaceutical significance due to its biologically confirmed pharmacological value.  Its poor solubility and 
bioavailability, however, stand as an impediment in further achieving higher levels of selective and specific 
biological effects toward disease therapeutics.  Metal ions, on the other hand, have been known to exert ben-
eficial action(s) at the cellular level through appropriate configuration of their coordination sphere, thereby 
formulating key interactions with molecular targets linked to the (patho)physiology of cells.  Vanadium is 
one of those transition metal ions, for which a diverse spectrum of reactivities have shown it to be useful in 
treatments of various diseases, including diabetes, cancer, and others.  In view of that metal ion’s flexibility 
to commit to (bio)chemical reactivity and curcumin’s known bioactivity, the potential of constructing binary 
and ternary vanadium-curcumin complex moieties (in the presence of ancillary ligands), conferring appro-
priately configured biological effects, was probed into through a carefully designed synthetic approach.  
Stoichiometrically-driven chemical reactivity between V(IV) and curcumin in alcoholic media, in the pres-
ence of a strong 2,2’-bipy chelator, led to the isolation and crystallization of compound 1.  This is one of the 
very rare examples of curcumin bound to a metal ion, in a coordination environment unraveled-confirmed 
through analytical, spectroscopic techniques and ultimately X-ray crystallography. 
The use of the ancillary ligand in the stabilization of the ternary V(IV)-curcumin-(2,2’-bipy) assembly (1) 
suggests that ternary systems of metal ion-natural organic binder chelators, incorporating N,N-aromatic che-
lators in the complexation process, may lead to isolable crystalline products amenable to full characteriza-
tion with enhanced hydrolytic stability of bound curcumin, as also reported elsewhere, with the VO+2 moie-
ty, and 1,10-phenanthroline  and dipyrido[3,2-α:2’,3’-c]phenazine as ancillary ligands [33].  In that respect, 
due consideration was given to the herein described synthetic efforts through which the ternary species 1 
arose and was further fully characterized analytically, spectroscopically, and crystallographically prior to 
being employed in biological activity experiments. 
The spectroscopic and crystallographic work revealed the presence of an octahedral complex in the solid 
state. The ternary complex was comprised of curcumin and 2,2’-bipy, with the two ligands introduced in the 
coordination sphere around V(IV) in a way that the vanadyl oxygen was positioned trans to the water mole-
cule bound to vanadium. This solid state picture was further investigated in solution, with EPR spectroscopy 
providing further insight into the solution behavior of the species.  In fact, the EPR-HYSCORE results sug-
gested the presence of yet another species, with the nitrogen donor anchors of the involved ligands posi-
tioned differently from the originally determined crystallographic arrangement in the solid state.  The poten-
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tial of an equilibrium between conformers of the ternary complex arising upon dissolution of the complex 
rose prominently.  To that end, a tedious yet detailed and comprehensive theoretical work involving diverse-
ly configured DFT calculations revealed the energetics of such a transformation that could be taking place, 
with the cis-conformer lying lower in energy that the trans-conformer observed crystallographically in the 
solid state (Table S2).  The details of such a potential conformational equilibrium in solution for the title 
complex stands in consonance to the suggestions of EPR spectroscopy and sheds further light into that be-
havior of such species containing V(IV) bound to two different ligands in an octahedral arrangement.  The 
presence of bound water in the coordination sphere of V(IV) introduces conformational diversity in the co-
ordination sphere configuration with the bulk of the organic chelator ligands measuring up to the labile 
monodentate inorganic water molecule in a conversion process (Fig. S1B) with cis- and trans-conformers 
emerging as participants in any further (bio)chemical reactivity pursued (vide infra). The specifics of such a 
transformation are quite revealing in projecting a well-defined specific energy profile of intermediates aris-
ing in the process (Fig. S1C), thereby signifying the importance of a comprehensive investigation of the sol-
id-state and solution behavior of species complemented by theoretical DFT calculations. 
4.2 The biological reactivity in a well-defined cellular environment 
The investigated biological activity of 1 is a direct consequence of its structural composition, appropriately 
formulated by the organic chelator moieties curcumin and 2,2’-bipy.  The presence of curcumin in the coor-
dination sphere of vanadium signifies the potential of that natural binder to influence metal ionic activity at 
the biological level.  Albeit difficult, at this point, to quantify the contribution of the aromatic chelator 2,2’-
bipy to the bioactivity of vanadium relative to that of curcumin, the presence of the latter provides an oppor-
tunity to focus on that natural product exerting metal-linked action at the cellular level. 
Curcumin has been an extensively used food additive, mainly in India and Southeast Asia, for many centu-
ries.  However, its safety and toxicity has been contradictory and extensively conjectured.  To our 
knowledge, there have been clinical studies in phase I conducted on humans, demonstrating curcumin toxici-
ty.  The results from a number of preclinical studies have demonstrated that curcumin may be helpful to the 
prevention and/or treatment of a spectrum of diseases, including Alzheimer’s Disease (AD), cancer, cystic 
fibrosis and inflammatory diseases [105].  A dose-dependent investigation was also conducted in order to 
specify the maximum tolerated dose and safety of a single dose of standardized powder extract of uniformly 
milled curcumin.  Curcumin tolerance at high single oral doses appears to be excellent and was considered 
safe for humans even (surprisingly-unexpectedly) at single oral administration doses as high as 12 g/day 
[106].  Only minimal toxicity experienced by participating subjects [seven out of twenty-four subjects 
(30%)] in relevant studies appeared to be dose-dependent.  A plethora of a) biological, beneficial, therapeu-
tic properties, including anti-oxidant, anti-inflammatory, anti-cancer activity, anti-HIV activity [107,108], or 
b) detrimental activity-effects were attributed to curcumin, including hepatoxicity, genotoxicity, and others 
[109-112].  Moreover, it’s worth noting that despite the paradox of curcumin displaying selective toxicity 
toward cancer cells, without influencing healthy cells, in vitro research demonstrated that curcumin can di-
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rect healthy human T cells toward apoptosis at a rate similar to that of cancerous leukemia cells [109].  A 
90-day administration of curcumin to rats showed that overdose or long term supplementation of curcumin 
could generate oxidative stress, inflammation, and metabolic disorders, probably causing liver damage [58].  
An extremely porous bio-Metal-Organic Framework (MOF), medi-MOF-1, was also synthesized from zinc, 
and a potential therapeutic agent with curcumin arose.  The Zn-based MOF demonstrated similar cell growth 
inhibitory performance through the MTT assay against pancreatic cancer cells (BxPC-3) and it was proposed 
as a potential drug for biomedical applications [58]. 
The anti-oxidant activity of many agents (compounds), including metal–curcumin complexes, has attracted 
considerable attention in the preventive and protective treatment of many diseases, such as neurodegenera-
tive diseases and others, e.g. scavenging reactive oxygen species (ROS), blocking Aβ-aggregation, and che-
lating neuro-toxic metal ions.  In this respect, it is well-established that curcumin is able to act as a powerful 
antioxidant by efficiently scavenging free radicals, i.e. ROS.  As a reasonable (logical) consequence, several 
metal-curcumin compounds have been synthesized in an attempt to exploit their possible antioxidant capaci-
ty.  To that end, antioxidant properties were reported for curcumin complexes of gallium, indium and vana-
dyl ions [113,114], as well as manganese [115], and copper [116].  The collective work shows that the be-
havior of the two compounds (curcumin and the title compound 1) appears to be one reflecting strong anti-
oxidant agents.  That, by all means, does not necessarily mean that a dose-dependent concentration effect 
applies to all concentrations tested, from low to high ones.  It appears, that at low concentrations (1-25 μΜ), 
the effects observed are commensurate with the antioxidant behavior of the two compounds, with compound 
1 being a stronger antioxidant agent than curcumin (under the employed experimental conditions).  When, 
however, the concentration rises to 40 and 50 μΜ, i.e. beyond a certain threshold concentration (which was 
discovered as a result of the experimental process in this work), the two compounds turn to pro-oxidant be-
havior, thus generating ROS species.          
Oxidative stress is considered one of the major causes of DNA damage.  Reactive oxygen species, generated 
during cell metabolism by various agents, could attack the DNA base guanine, forming 8-OHdG lesions, 
known to possess mutagenic properties, thereby having 8-OHdG routinely used as a biomarker for carcino-
genesis [117].  A number of studies are being currently conducted on transition metal complexes, other than 
cisplatin, targeting the discovery of more efficient and less toxic anticancer agents.  In that respect, 
knowledge and delineation of the binding mode(s) of various metal complexes, candidates for chemothera-
peutic agents, to nucleic acids, is of crucial significance to the development of such new efficient drugs. 
Thus, targeted research in the metallo-drug field revolves around the design of compounds preferably target-
ing DNA binding through non-covalent modes of action, such as binding to major and minor grooves of the 
double helix, phosphate clamps, and insertion or intercalation [118-121].  However, whereas groove binding 
modes cause only negligible distortions to the B-form structure of the DNA double helix, the intercalation 
mode of binding promotes the most dramatic alterations in the DNA structure.  A crucial factor influencing 
the binding mode is molecular structure, e.g. extended planar aromatic rings capable of interposing between 
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paired DNA bases through π-stacking, thereby inducing considerable unwinding, lengthening and destabili-
zation of the double helix [122,123]. 
Although previous in vitro experiments had demonstrated that curcumin alone may cause DNA damage to 
human cells in both peripheral blood lymphocytes [124], and gastric mucosal cells [125], recent work using 
similar doses of curcumin did not report DNA damage caused by curcumin to T cells [126].  The authors of 
the study on T cells attributed this discrepancy to the different populations of cells used in the two experi-
ments and perhaps the different methods used in testing DNA damage [104].  Moreover, another in 
vitro study conducted on a human fibrosarcoma cell line reported evidence of DNA damage initiated at low 
curcumin concentrations in the range 3-8 μM, whereas apoptosis was stimulated at concentrations ~10 μM 
[127].  The in vitro experiments in the present study, examining the direct effect of both curcumin and ter-
nary compound 1, showed DNA degradation at curcumin concentrations >25 μΜ (Fig.14A-B).  An aniso-
tropic interaction with the DNA helical structure of two new heterolepticpentacoordinatedZn(II) complex-
es,containing 4,4´-disubstituted 2,2´-bipyridines and curcumin as an ancillary ligand, has been demonstrated. 
This analysis shows that the interaction mode of curcumin with DNA in the double helix favors their align-
ment perpendicular to the DNA axis, suggesting partial inter-base intercalation of these Zn(II) complexes 
[128].  Given the composition and formulation of the coordination sphere of V(IV) in the presence of 2,2’-
bipy and curcumin, it is not unlikely that a similar interactive mode, encompassing intercalation and/or 
groove binding, with DNA evolves through chemical reactivity with 1.  Further work on the issue, taking 
into consideration the influence-contribution of both ligands to the activity of 1, is currently ongoing in our 
lab.  Overall, the collective biological behavior of the title compound reflects its vanadium-heteroligand 
complex nature supported by the spectroscopic and theoretical data.  
5. Conclusions 
The need to develop efficient natural product-containing drugs counteracting pathophysiological conditions 
led to the synthetic exploration of the ternary V(IV)-curcumin-(2,2’-bipy) system, which led to the isolation 
of an unusual ternary complex of vanadium [VO(C21H19O6)(C10H8N2)(H2O)]2(SO4)
.2CH3OH
.3H2O (1).  The 
detailed physicochemical characterization of the fundamental assembly in 1a) projected a well-defined coor-
dination environment for V(IV), containing a stabilized curcumin moiety and an ancillary aromatic chelator 
(2,2’-bipy), all important ingredients in an optimally configured environment of soluble-bioavailable curcu-
min bio-activity, and b) provided insight into key attributes of the formulated ternary vanado-species, in the 
solid-state and in solution, supported by analytical, crystallographic, spectroscopic and theoretical studies, 
further enabling its employment in biological studies relevant to the probe of the antioxidant potential of 
curcumin. The ternary V(IV)-curcumin-(2,2’-bipy) compound 1exhibits significant anti-ROS/anti-oxidant 
activity in yeast cells, in fact reflecting greater potential than curcumin itself.  Counter-ROS activity emerg-
es significantly even at very low levels (2.5 μΜ).  Compound 1 was also able to lower MDA levels both in-
side the cells (in the range 5-25 μΜ) and in the extracellular growth medium (2.5 μΜ).  Furthermore, the 
title compound could be considered non-toxic at levels up to 10μΜ.  It does not inhibit cell metabolism by 
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comparison to curcumin, as proven through the FDA-lytic activity.  More in-depth work, however, is needed 
to delineate the in vitro and in vivo action of 1 on DNA, as in vitro experiments indicate potential genotoxi-
city.  The effect on DNA may be attributed to a possible intercalation mode of action rather than an altera-
tion of the cellular oxidative status, which seems to be improved.  Collectively, the experimental results pro-
vide a global picture for the biological activity of curcumin, which upon vanadium coordination in the pres-
ence of 2,2’-bipy delivers biological activity, thereby enhancing its antioxidant character and setting the ba-
sis for the development of new metal-complexed curcumin pharmaceuticals capable of counteracting 
(sub)cellular pathophysiologies. 
 
Appendix A. Supplementary data 
CCDC 1567352 (1) contains the supplementary crystallographic data for this paper.  These data can be ob-
tained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallograph-




Aβ    Amyloid-β 
AD    Alzheimer’s Disease 
PDT   Photodynamic therapy 
2,2’-bipy  2,2’-bipyridine     
UV-Vis  UV-visible 
ESI-MS  Electrospray Spray Ionization mass spectrum 
FT-IR   FT-Infrared 
TGA  Thermogravimetric analysis 
EPR  Electron Paramagnetic Resonance 
DFT  Density Functional Theory 
DOS   Density of States  
NEB  Nudged Elastic Band 
DMSO-d6  Deuterated dimethyl sulfoxide 
FDA  Fluorescein diacetate 
HYSCORE  Hyperfine sublevel correlation spectroscopy 
S. cerevisiae  Saccharomyces cerevisiae 
MDA  Malondialdehyde 
TCA  Trichloroacetic acid 
TBA  Thiobarbituric acid 
ROS  Reactive oxygen species 
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NBT  Nitrobluetetrazolium chloride 
dsDNA  Double-stranded DNA 
CT-dsDNA  Calf thymus dsDNA 
EtBr  Ethidium bromide 
LMCT  Ligand to metal charge transfer 
CHEQ  Chelation enhancement of quenching 
SEM  Scanning Electron Microscopy 
PAS  Principal axis system  
HFI  Hyperfine interaction 
pDNA  plasmidDNA 
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R values are based on F values, Rw values are based on F2;  w=w′ × [1 - (ΔFobs / 6 × ΔFest)²]²  
where w’=[P0T0′(x) + P1T1′(x) + ... Pn-1Tn-1′(x)]
-1 and  Pi are the coefficients of a Chebychev series in ti(x), and x 





molecular mass 1431.23 
T, oK 295 
radiation type MoKa 
wavelength, λ (Ǻ) 0.71073 
crystal system monoclinic 
space group C2/c  
a (Ǻ) 30.117(4) 
b (Ǻ) 15.545(2) 
c (Ǻ) 15.940(3) 
α, deg 90° 
β, deg 116.180(17)° 
γ, deg 90° 




abs.coeff. (μ), mm-1 0.39 
range of h,k,l -36→32, -18→18, 0→19 
goodness-of-fit on F2 1.0000 
Measured, independent 

















Table 4: Simulation parameters using two coupled 14N nuclei for the spectrum shown in Fig. 
9B (set 1). 
 Tensorb 1 2 3 iso (Euler angles in )a 
N1 
        
HFI 7.32 5.67 6.00 6.33 0 0 0 
        
NQI 1.50 0.65 0.85  0 0 90 
 K0.75 0.13      
N2 
        
HFI 7.32 5.67 6.00 6.33 0 0 75 
        
NQI 1.50 0.65 0.85  0 0 165 
 K0.75 0.13      
a Active rotation. 
b Principal values of tensors in MHz. 
























Table 5: Simulation parameters using two coupled 14N nuclei for the spectrum shown in Fig. 
9C (set 2). 
 Tensorb 1 2 3 iso (Euler angles in )a 
N1 
        
HFI 7.32 5.67 6.00 6.33 0 0 0 
        
NQI 1.50 0.65 0.85  0 0 90 
 K0.75 0.13      
N2 
        
HFI 1.00 1.20 0.60 0.93 0 0 0 
        
NQI 1.80 0.63 1.17  0 90 0 
 K0.90 0.30      
a Active rotation. 
b Principal values of tensors in MHz.  
Figure Captions 
Figure 1: Partially labeled plot of 1. Hydrogen atoms were omitted for clarity. Color code: 
V, purple; O, red; N, blue; C, white. 
Figure 2: ESI-MS spectrum of 1. 
Figure 3:  Solution 1H (A) and 13C-NMR (B) spectra of 1inDMSO-d6.Thepeaks, marked as 
S, are due to the solvent. 
Figure 4:  A.UV-Visible spectra of 1(black line) and pure curcumin (red line). 
 B.Concentration-dependent UV-Visible spectrum of 1 at various(concentrations 
>10-6 M).  
Figure 5:  Fluorescence spectra of 1and pure curcumin. 
Figure 6:  TGA diagram of 1. 
Figure 7: Graph ofμeff and μeff*T of 1with temperature in a field of μ0H = 1 T (10000 Oe). 
Figure 8: CW-X-band experimental (solid line) and theoretical (dotted line) EPR spectrum 
of 1 in frozen methanol/toluene solution. EPR conditions: Temperature 70K, 
Modulation amplitude5 Gpp, microwave power20 μW, microwave frequency 
9.704 GHz. 
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Figure 9: (A) Experimental HYSCORE spectrum of 1 in methanol/toluene frozen solution 
(1:1) measured at the g observer position, B=336.6 mT.Three spectra measured 
with  = 120 ns,  = 144 ns, and  = 168 ns are summed in order to reduce the 
blind spot effect. Experimental parameters: t/2 = 16 ns; time increment, Δt = 24 
ns (data matrix 180×180). A four-step phase cycle was used to removeunwanted 
echoes.(B) and(C) simulations of (A) with two different systems (for simulation 
parameters see text). 
Figure 10:  (A) Total density of states (solid black line) as well as individual contributions 
from V atoms (red line), O atoms (green line), C atoms (black solid line), N at-
oms (blue solid line), S atoms (blue dashed line), and H atoms (brown line) for 
the vanadium-curcumin complex extracted using Density Functional Theory. 
 (B) DOS projected partial charge density of one out of eight vanadium-curcumin 
complexes included in the simulation unit cell.  It corresponds to states between 
the conduction band minimum and the Fermi level, EF (Fig. 10A).  The isosur-
face was set to a saturation level of 0.01. 
Figure 11:  The difference in total energy between trans and cis as well as seven intermedi-
ate conformers extracted via the NEB method (Section 2.1.9). 
Figure 12: Comparative percent fungal growth before (100%) and after exposure of S. 
cerevisiae cells to various concentrations of curcumin and 1.Yeast cells grown 
in MMS medium for 24 h with several concentrations (2.5, 5, 10, 20, 25, 40, and 
50 μΜ) of pure curcumin (orange bars) and 1 (red bars). Growth has been de-
terminedthrough turbidity measurements (A600).  Both pure curcumin (black 
line) and compound 1 (red line) inhibitedyeastgrowth with increasing concentra-
tions, with1inhibiting cell growth to a greater extent than pure curcumin.  Statis-
tical significance compared to control: p>0.05 (ns), p<0.05 (*), p<0.01 (**) and 
p<0.001(***). 
Figure 13: (A)Viability of S. cerevisiae cells in the absence of any compound (%) and 
presence of various concentrations of curcumin and compound 1. Yeast cell via-
bility at various concentrations (2.5, 5, 10, 20, 25, 40, and 50 μΜ) of pure cur-
cumin (orange bars) and compound 1 (red bars) compared to control, as deter-
mined through enzymatic hydrolysis of FDA for 1 h at 37 oC.(B)Viability of S. 
cerevisiae cells in the presence of curcumin 5 μΜ (green line) and 25 μΜ (tur-
quoise), 5 μΜ (blue line) and 25 μΜ (fuchsia line) of compound 1,and in the ab-
35 
sence of any compound (control, red line). Fluorescence was measured at λex= 
455 nm and λem(max) = 515 nm. The fluorescence of the hydrolyzed product 
was measured after excitation at λex = 494 nm and emission at wavelengths be-
tween λem500-560 nm, with a peak at about 523 nm.  Results, as graphed in 
(B),show that pure curcumin disturbs significantly yeast cell metabolic activity, 
as that is reflected into decreased enzymatic hydrolysis. Statistical significance 
compared to control: p>0.05 (ns), p<0.05 (*), p<0.01 (**) and p<0.001(***). 
Figure 14:  Levels of hyper-oxidized lipid products, namely MDA, generated by fungal S. 
cerevisiae cells exposed to various concentrations of curcumin and compound 1 
intracellularly (A),and secreted extracellularly(B). Cells were grown in the pres-
ence of several concentrations (2.5, 5, 10, 20, 25, 40, and 50 μΜ) of pure cur-
cumin (orange bars) or compound 1 (red bars), and centrifuged.  The cells were 
boiled in a lysis buffer containing100 mMNaCl, 1% (w/v) SDS, 2% (v/v) Triton 
X-100, 10 mMTris-HCl pH 8.00, and 1mM EDTA followed by ultrasound 
treatment. A volume of 500μL of a 0.67% TBA, 20% (w/v) buffer,was added to 
the same volume of lysate or growth medium, and the colored product was 
measured at 535 nm. The graphs (orange for pure curcumin, red for compound 
1) show no significant changes in intracellular MDA concentration, with the ex-
ception of 5 μΜ of both compounds (-25% compared to control), for tested con-
centrations in the range from 5 to 25 μΜ of both compounds, whereas increased 
MDA levelswere observed extracellularly for both pure curcumin and com-
pound 1. Statistical significance compared to control: p>0.05 (ns), p<0.05 (*), 
p<0.01 (**) and p<0.001(***). 
Figure 15:  Intracellular levels of free ROS (O2
−•)in yeast cells. Cells were grown in the 
presence of several concentrations (2.5, 5, 10, 20, 25, 40, and 50 μΜ) of curcu-
min (orange bars) or compound 1 (red bars) and centrifuged. The recovered cells 
were dispersed in100 μL of MMS growth medium and 500 μL of 1 mg.mL-
1NBT. After the reaction, the formazan product was dissolved and the absorb-
ancewas measured at 575 nm. Free ROS decreased significantly in the presence 
of a wide range of compound 1 concentrations (up to 90% drop at 25 
μΜ).Statistical significance compared to control: p>0.05 (ns), p<0.05 (*), 
p<0.01 (**) and p<0.001(***). 
Figure 16:  (A) Agarose (1%) gel electrophoresis of CT-dsDNA. Each sample containing 3 
μg of CT-dsDNAwas treated with curcumin or compound 1 at 37oC for 1 h; 
36 
Lane M: Molecular weight markers, 1 kb ladders. Lanes 1-8:CT-dsDNA treat-
ed with 2.5, 5, 10, 20, 25, 40, and 50 μΜ of pure curcumin. Lane C: control, 
CT-dsDNAwithout treatment; Lanes 1´-8´:CT-dsDNA treated with the same 
concentrations ofcompound 1. 
(B)Quantification of DNA integrity (%) of the main band of the CT-
dsDNAfollowing treatment in vitro with various concentrations ranging from 
2.5, 5, 10, 15, 20, 25, 40, and 50 μΜ of curcumin (Lanes 1-8) and compound 
1(Lanes 1´-8´) of the agarose gel Fig. 16A.Statistical significance compared to 
control: p>0.05 (ns), p<0.05 (*), p<0.01 (**) and p<0.001(***). 
(C) Agarose (1%) gel electrophoretic pattern of an (EtBr)-stained mixture of 
supercoiled (S) and relaxed (R) pDNA (pUC18) after 1 h of electrophoresis. S 
represents the supercoiled, R the relaxed, D the dimer, M the multimer, and L 
the linear form of pDNA (pUC18).  Each sample containing 3 μg of pDNAwas 
treated with curcumin orcompound 1at 37 oC for 1 h; Lanes 1-7:plasmid DNA 
treated with 2.5, 5, 10, 15, 20, 25, and 50 μΜ of curcumin.Lane C: control, 
plasmid DNA without treatment.Lanes 1´-7´: plasmid DNA treated with the 
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Figure 16 C 
M      1     2 3   4  5   6   7    8    C      1´    2´    3´    4´    5´    6´    7´     8´ 
